Fundraising Fox
Kypha
St. Louis, US · Founded 2009 · Delaware corporation · 11 employees on LinkedIn · 4 known investors
Find your way into Kypha
Sign up to see every warm intro you have to Kypha
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Kypha team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Kypha develops clinical diagnostic tests for immune system biomarkers, particularly complement activity markers, and provides solutions for real-time immune insights across therapeutic areas. The company serves biopharma firms, clinical laboratories, and medical institutions through a network of clinical collaborators and research partners.
Founders & leadership
NS
Nick StatenExecutiveHe has led clinical studies in intraoperative imaging and brings expertise in regulatory submissions (IND, 510(k), and de novo), preclinical and clinical development, and quality management systems for medical devices.
PK
Paul K. OlsonExecutive
Board
DS
JD
James D. MarselisBoard director
JS
Jonathan SackierBoard director
RC
R. Charles MoyerBoard director
TV
T. Vernon FosterBoard director
Investors · 4
BioGenerator Ventureslisted by BioGenerator VenturesSt. Louis · $50K – $250K
How we know: BioGenerator Ventures's portfolio page · Not right? Tell us
Missouri Technology Corporationlisted by Missouri Technology CorporationSt. Louis
How we know: Missouri Technology Corporation's portfolio page · Not right? Tell us
ArsenalreportedNew York
How we know: press coverage · Not right? Tell us
Serra VenturesreportedChampaign · $5M
How we know: the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$14.3M disclosed across 6 rounds · 2011–2022
▶$5.2MraisedMay 2022 · 13 investors · Other Health CareRule 506(b)
▶$5.2MraisedMay 2022 · 13 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Chad StieningExecutive Officer, Director
- Gerhard BetteDirector
- Dennert WareDirector
- James MerselisDirector
- Peter ReineckeDirector
- Offering amount
- $17M
- Amount sold
- $5.2M
- Minimum investment
- $1
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$950KraisedJul 2018 · 1 investors · Other Health CareRule 506(b)
▶$950KraisedJul 2018 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Peter ReineckeDirector
- James MerselisDirector
- Jonathan SackierDirector
- Chad StieningExecutive Officer, Director
- Offering amount
- $950K
- Amount sold
- $950K
- Minimum investment
- $1
- First sale
- Jun 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.5MraisedMay 2018 · 13 investors · Other Health CareRule 506(b)
▶$5.5MraisedMay 2018 · 13 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- James MerselisDirector
- Jonathan SackierDirector
- Chad StieningExecutive Officer, Director
- Peter ReineckeDirector
- Offering amount
- $7.9M
- Amount sold
- $5.5M
- Minimum investment
- $1
- First sale
- Apr 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.1MraisedNov 2015 · 3 investors · Other Health CareRule 506(b)
▶$2.1MraisedNov 2015 · 3 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Nick StatenExecutive Officer
- T. Scott GloverExecutive Officer
- James D. MarselisDirector
- Peter ReineckeDirector
- Jonathan SackierDirector
- David SmollerDirector
- Chad StieningDirector
- Offering amount
- $3.2M
- Amount sold
- $2.1M
- Minimum investment
- $15K
- First sale
- Feb 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$398.4KraisedJan 2014 · 1 investors · PharmaceuticalsRule 506(b)
▶$398.4KraisedJan 2014 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David SmollerDirector
- Chad StieningExecutive Officer, Director
- Peter ReineckeDirector
- Peter A. TakesExecutive Officer
- Sultan MeghjiDirector
- Nick StatenExecutive Officer
- Paul OlsonExecutive Officer, Director
- Offering amount
- $3.5M
- Amount sold
- $398.4K
- Minimum investment
- $1
- First sale
- Dec 2013
- Incorporated
- Corporation, Delaware, 2009
- Federal exemptions
- 06b
▶$206KraisedJan 2012 · 10 investors · BiotechnologyRule 506(b)
▶$206KraisedJan 2012 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Chad M. StieningExecutive Officer, Director
- R. Charles MoyerDirector
- Paul K. OlsonExecutive Officer, Director
- T. Vernon FosterDirector
- Offering amount
- $500K
- Amount sold
- $206K
- Minimum investment
- $8K
- First sale
- Nov 2011
- Incorporated
- Corporation, Delaware, 2009
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Qpex BiopharmaQpexBio develops anti-infective drugs designed to overcome multidrug resistance, improving existing drug classes and discovering new ones for use in combination with known anti-infectives against drug-resistant bacteria. The company operates R&D laboratories in San Diego, California, working alongside Shionogi's research labs in Japan.
Companies working in the same space as Kypha.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $218.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2011 | $273.5K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Kypha do?
- Kypha develops clinical diagnostic tests for immune system biomarkers, particularly complement activity markers, and provides solutions for real-time immune insights across therapeutic areas. The company serves biopharma firms, clinical laboratories, and medical institutions through a network of clinical collaborators and research partners.
- Who are Kypha's investors?
- Kypha's investors include BioGenerator Ventures, Missouri Technology Corporation, Arsenal, Serra Ventures.
- How much funding has Kypha raised?
- Kypha has disclosed $14.3M raised across 6 rounds.
- Where is Kypha headquartered?
- Kypha is headquartered in St. Louis, US.